Skip to main content
. 2022 Aug 10;47(4):E299–E310. doi: 10.1503/jpn.210191

Table 2.

Difference in repeated behaviours and global improvement among participants with autism spectrum disorder taking antidepressants versus placebo — subgroup analysis

Characteristic No. of trials Hedges g (95% CI)* Z score Cochran Q p value
Stereotyped behaviours
 Drug intervention
  SSRI 7 0.25 (0.03 to 0.48) 2.21§ 0.55 0.005
  Clomipramine (TCA) 3 0.45 (−0.01 to 0.90) 1.93
 Age group
  Children and adolescents 8 0.21 (0.09 to 0.38) 2.64§ 1.94 0.001
  Adults 3 0.58 (0.11 to 1.04) 2.29§
Global improvement
 Drug intervention
  SSRI 5 1.04 (−0.04 to 2.12) 1.90§ 0.20 0.007
  Clomipramine (TCA) 3 1.45 (0.02 to 2.89) 1.98§
 Age group
  Children and adolescents 6 0.59 (−0.09 to 1.27) 1.69 1.49 0.040
  Adults 3 2.41 (−0.44 to 5.25) 1.66

CI = confidence interval; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

*

Random-effects model.

For heterogeneity assessment based on random-effects analysis.

Significance of the difference between effect sizes in the subgroups.

§

p < 0.05.